Align Technology (NASDAQ:ALGN) price target raised to $355.00 by Barclays

ME Staff
-
0

Analyst Ratings For Align Technology (NASDAQ:ALGN)

Today, Barclays raised its price target on Align Technology (NASDAQ:ALGN) to $355.00 per share.

There are 14 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Align Technology (NASDAQ:ALGN) is Buy with a consensus target price of $334.2857 per share, a potential 12.52% upside.

Some recent analyst ratings include

  • 4/25/2019-Align Technology (NASDAQ:ALGN) had its Overweight rating reiterated by Piper Jaffray Companies with a $350.00 price target
  • 4/17/2019-Align Technology (NASDAQ:ALGN) has coverage initiated with a Buy ➝ Buy rating and $335.00 price target
  • 2/14/2019-Align Technology (NASDAQ:ALGN) gets downgraded to Neutral by UBS Group with a price target of $275.00
  • On 2/28/2019 Joseph Lacob, Director, sold 20,000 with an average share price of $258.31 per share and the total transaction amounting to $5,166,200.00.
  • On 2/25/2019 Yuval Shaked, Director, sold 400 with an average share price of $255.52 per share and the total transaction amounting to $102,208.00.
  • On 2/12/2019 Julie Tay, SVP, sold 1,250 with an average share price of $254.58 per share and the total transaction amounting to $318,225.00.
  • On 11/30/2018 Christopher C. Puco, VP, sold 8,764 with an average share price of $227.42 per share and the total transaction amounting to $1,993,108.88.
  • On 11/30/2018 Joseph Lacob, Director, sold 10,000 with an average share price of $231.82 per share and the total transaction amounting to $2,318,200.00.
  • On 11/27/2018 Sreelakshmi Kolli, SVP, sold 5,000 with an average share price of $223.15 per share and the total transaction amounting to $1,115,750.00.
  • On 8/29/2018 Simon Beard, SVP, sold 3,895 with an average share price of $384.48 per share and the total transaction amounting to $1,497,549.60.

About Align Technology (NASDAQ:ALGN)
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontics, and restorative and aesthetic dentistry worldwide. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign Comprehensive treatment that addresses the orthodontic needs of teenage patients, such as compliance indicators and compensation for tooth eruption; Invisalign Assist treatment, which offers support to dental practitioners throughout the treatment process, including progress tracking; and Invisalign First Phase I and Invisalign First Comprehensive Phase II package for younger patients with early mixed dentition with a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign Express 10, Invisalign Express 5, Express Package, Lite Package, Invisalign Go, and SmileDirectClub; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers; computer-aided design/computer-aided manufacturing services and ancillary products, such as disposable sleeves for the wand; and iTero applications and tools. The company was founded in 1997 and is headquartered in San Jose, California.

Recent Trading Activity for Align Technology (NASDAQ:ALGN)
Shares of Align Technology closed the previous trading session at 297,08 up +1,00 0,34 % with 296 shares trading hands.